Hims & Hers Health Ranks 47th in Trading Volume with 14.76 Billion Shares Exchanged Amidst Weight Loss Drug Boom

On May 27, 2025, Hims & Hers Health (HIMS) experienced a trading volume of 14.76 billion, ranking 47th in the day's stock market activity. The stock closed with a 2.68% decrease.

Hims & Hers Health has seen significant growth this year, with its stock price more than doubling. The company's success can be attributed to its online healthcare platform, which initially gained popularity for making it easier to obtain prescriptions for erectile dysfunction drugs and hair growth treatments. However, the company's fortunes took a dramatic turn with the introduction of its compounded GLP-1 injectables for weight loss.

The Food and Drug Administration's shortage list for Wegovy, a popular weight loss drug produced by Novo Nordisk, created a legal loophole for compounding pharmacies to produce and sell their own versions. Hims & Hers capitalized on this opportunity, offering its own GLP-1 drug at more aggressive discounts than Novo Nordisk's name-brand versions. This move significantly accelerated the company's revenue growth, which had already been increasing by at least 65% annually for the past six years.

Despite initial concerns that the market for compounded GLP-1 drugs would diminish as Novo Nordisk ramped up production, Hims & Hers managed to secure a deal with the pharmaceutical giant. This agreement allowed Hims & Hers to sell discounted monthly subscriptions of Wegovy, further bolstering its market position. Additionally, the company reported strong first-quarter earnings, with management forecasting continued growth in its non-compounding business segments.